KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults.

Yun Xie, Qingfeng Li, Hongyi Zhao, Zuoliang Qi, Jiaming Sun, Qian Tan, Dong Li, Zhiqi Hu, Ziyang Liu, Smita Chawla

Aesthet Surg J 45(7) 699-708

PMID40246546
PMCIDPMC12168443
DOI10.1093/asj/sjaf033
发表日期2025-04-17
入排依据:未发现恶性肿瘤人群证据。
已检查 8 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 3 张未列出。
摘要

摘要

BACKGROUND: Individuals with chin retrusion may seek chin and lower jawline aesthetic enhancement. OBJECTIVES: To evaluate VYC-25L (Juvéderm Volux XC; Allergan Aesthetics, an AbbVie company), a lidocaine-containing injectable hyaluronic acid dermal filler, for chin retrusion correction. METHODS: In this prospective, Phase 3, multicenter study (NCT04559984), Chinese adults with moderate-to-severe chin retrusion on the China (Allergan) Chin Retrusion Scale (CACRS) and glabella-subnasale-pogonion (G-Sn-Pog) angle <172.5° were randomized 2:1 to VYC-25L (treatment plus optional touch-up 4 weeks later) or no treatment (control). The primary endpoint was change from baseline (CFB) in G-Sn-Pog angle at Week 24. Secondary endpoints included CACRS response (≥1-point improvement), Global Aesthetic Improvement Scale (GAIS) response (improved/much improved), and FACE-Q Satisfaction with Chin score. Procedural pain was rated (0 = none to 10 = worst imaginable); injection-site responses (ISRs) were recorded daily for ≤28 days. RESULTS: The mean age of the patient (VYC-25L, n = 97; control, n = 51) was 31.2 years (range, 20-52 years). Mean CFB in G-Sn-Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control; between-group difference, 3.08° [P < .0001]); improvement was maintained to Week 52. At Week 24, VYC-25L achieved higher responses vs control for CACRS (78.7% vs 18.8%, respectively; rate difference, 60.0%; P < .0001) and GAIS (92.6% vs 4.2%, respectively; rate difference, 88.4%; P < .0001); mean overall FACE-Q Satisfaction with Chin score was 70.4 vs 34.9, respectively. Mean (standard deviation) procedural pain was 2.6 (1.6); most ISRs were mild (41.8%) or moderate (50.0%) in severity. CONCLUSIONS: In Chinese adults, VYC-25L safely and effectively corrected chin retrusion for at least 1 year.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(8,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Study design. G–Sn–Pog, glabella–subnasale–pogonion; W, week.
非 KM Figure
Figure 2Figure 2. China (Allergan) Chin Retrusion Scale. © 2025 AbbVie. Used with permission.
非 KM Figure
Figure 3Figure 3. Mean change from baseline in G–Sn–Pog angle over time through Week 52. G-Sn-Pog, glabella–subnasale–pogonion; W, week.
非 KM Figure
Figure 4Figure 4. China Allergan Chin Retrusion Scale responder rates at all time points. CACRS, China Allergan Chin Retrusion Scale.
非 KM Figure
Figure 5Figure 5. GAIS responder rates at all time points. (A) Evaluating investigator-assessed GAIS responder rates. (B) Patient-assessed GAIS responder rates. GAIS, Global Aesthetic Improvement Scale.
非 KM Figure
Figure 6Figure 6. FACE-Q Satisfaction with Chin Scale scores at all time points.
非 KM Figure
Figure 7Figure 7. Representative photographs of patients before and after receiving VYC-25L showing improvements in the G–Sn–Pog angle. (A and C) Participant A (female aged 21 years) at baseline. CACRS score: 4; G–Sn–Pog angle: 165°. (B and D) Participant A (female aged 21 years) at Week 24 posttreatment. Total injected volume: 1.65 mL; CACRS score: 1; G–Sn–Pog angle: 169°; angle change from baseline: 4°. (E and G) Participant B (female aged 29 years) at baseline. CACRS score: 3; G–Sn–Pog angle: 165°. (F and H) Participant B (female aged 29 years) at Week 24 posttreatment. Total injected volume: 2 mL; CACRS score: 1; G–Sn–Pog angle: 169°; angle change from baseline: 4°. (I and K) Participant C (female aged 30 years) at baseline. CACRS score: 3; G–Sn–Pog angle: 166°. (J and L) Participant C (female aged 30 years) at Week 24 posttreatment. Total injected volume: 3.1 mL; CACRS score: 1; G–Sn–Pog angle: 169°; angle change from baseline: 3°. (M and O) Participant D (female aged 37 years) at baseline. CACRS score: 3; G–Sn–Pog angle: 159°. (N and P) Participant D (female aged 37 years) at Week 24 posttreatment. Total injected volume: 3.5 mL; CACRS score: 2; G–Sn–Pog angle: 162°; angle change from baseline: 3°. CACRS, China Allergan Chin Retrusion Scale; G-Sn-Pog, glabella–subnasale–pogonion.
非 KM Figure
Figure 8Figure 8. Injection-site responses after initial treatment. ISR, injection-site response.
非 KM Figure